Blog
RSS FeedPosted by Michael Wonder on 01 Dec 2020
ICER releases draft evidence report on therapies for anaemia in chronic kidney disease
30 November 2020 - Public comment period now open until 5 January 2021; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 30 Nov 2020
ICER Analytics launched to accelerate the real world application of ICER reports, helping payers, the life science industry, and health care policy makers move from insight to action
30 November 2020 - The Institute for Clinical and Economic Review today formally launched ICER Analytics, a new cloud-based platform that ...
Posted by Michael Wonder on 22 Nov 2020
ICER publishes final report and policy recommendations for haemophilia A therapies
20 November 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of emicizumab over factor ...
Posted by Michael Wonder on 19 Nov 2020
Consideration of value-based pricing for treatments and vaccines is important, even in the COVID-19 pandemic
19 November 2020 - Prices send signals about consumer preferences and thus stimulate producers to make more of what people want. ...
Posted by Michael Wonder on 10 Nov 2020
ICER provides second update to pricing models for remdesivir as a treatment for COVID-19
10 November 2020 - Based on an analysis of four studies evaluating remdesivir’s influence on mortality, ICER has concluded that the ...
Posted by Michael Wonder on 21 Oct 2020
ICER posts draft scoping document for the assessment of Alzheimer’s disease
21 October 2020 - Document open to public comment until 10 November 2020. ...
Posted by Michael Wonder on 20 Oct 2020
Biden looks to Germany for answers on how to tackle high U.S. drug prices
20 October 2020 - With the U.S. election just two weeks away, Democratic presidential nominee Joe Biden is offering clues ...
Posted by Michael Wonder on 10 Oct 2020
In landmark international program, HTA agencies around the world access ICER's customisable COVID-19 cost-effectiveness model
9 October 2020 - Leveraging ICER’s new cloud-based Interactive Modeler platform, Quebec’s HTA agency has used the COVID-19 model to inform ...
Posted by Michael Wonder on 29 Sep 2020
ICER to assess treatment for Alzheimer’s disease
29 September 2020 - Report will be subject of CTAF meeting in May 2021; open Input now being accepted until ...
Posted by Michael Wonder on 28 Sep 2020
ICER publishes white paper on cornerstones for fair patient access to prescription drugs, launches annual assessment of US payer policies
28 September 2020 - Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, white paper ...
Posted by Michael Wonder on 23 Sep 2020
ICER issues final report and policy recommendations on treatments for cystic fibrosis
23 September 2020 - Independent appraisal committee unanimously concludes that Trikafta delivers substantial benefits for patients, family members, and society. ...
Posted by Michael Wonder on 22 Sep 2020
ICER posts draft scoping document on therapies for multiple myeloma
22 September 2020 - Document open to public comment until 13 October 2020. ...
Posted by Michael Wonder on 11 Sep 2020
ICER publishes evidence report on targeted immune modulator therapies for ulcerative colitis
11 September 2020 - All assessed therapies provide significant health benefits, but even after rebates, all are priced at levels ...
Posted by Michael Wonder on 31 Aug 2020
ICER posts draft scoping document on lupus nephritis
31 August 2020 - Document open to public comment until 21 September 2020. ...
Posted by Michael Wonder on 15 Aug 2020
Many psoriasis patients are paying higher prices than ever at the pharmacy counter
13 August 2020 - Over the past decade, wholesale prices for self-administered psoriasis medicines rose substantially, underscoring the ongoing financial ...